7 results about "Bone marrow suppression" patented technology

This invention belongs to the field of animal model construction technology, specifically relating to a mouse immunosuppressive model that maintains a long-term immunosuppressive state, its construction method, and its application. This invention establishes a stable immunosuppressive state model with reduced neutrophil count and no significant decrease in erythrocyte count by administering different doses of immunosuppressants (10-50 mg / kg body weight) to Balb / c mice via a combination of "reduced total dose + multiple gavage administration + satellite monitoring." The method for constructing this mouse immunosuppressive model reduces drug usage, controls neutrophil count rebound, establishes a stable model of reduced neutrophil count, and avoids deep bone marrow suppression (i.e., does not cause an uncontrollable decrease in erythrocyte or platelet count), which is beneficial for long-term experimental conduct and drug evaluation.

The application discloses a high-safety tumor treatment preparation based on a prodrug-enzyme-neutralizing antibody three-system, and a preparation method and application thereof. The preparation comprises three core components: (a) a prodrug, which is coupled by an anti-tumor drug (such as doxorubicin) and cephalosporin; (b) an activating enzyme, such as beta-lactamase, which is specifically expressed in the tumor by phage, catalyzes the hydrolysis of the prodrug, and releases the active drug; and (c) a neutralizing antibody, such as an anti-doxorubicin monoclonal antibody, which can specifically bind and neutralize the active drug overflowing into the blood circulation. The application first integrates the precise killing strategy of "prodrug-local activation" and the safety strategy of "neutralizing antibody-systematic protection" into a complete treatment closed loop, utilizes the "differential neutralization" characteristics of the anti-doxorubicin antibody, effectively protects normal tissues from toxic damage under the premise of not affecting the local efficacy of the tumor, and significantly improves the therapeutic index of the chemotherapy drug, reduces the side effects such as cardiotoxicity and bone marrow suppression, and provides a new paradigm with high efficiency and safety for tumor treatment.

This invention discloses a yam vesicle nanomaterial, its preparation method, and its application for reducing the toxicity of radiotherapy for breast cancer. It belongs to the field of biomedical technology. The method includes adding PBS to the yam at a weight-to-volume ratio of 1:3 for juicing, sieving the yam juice, centrifuging the resulting yam filtrate at low speed to obtain supernatant A, centrifuging supernatant A at medium speed to obtain supernatant B, centrifuging supernatant B at ultra-high speed, resuspending the precipitate in PBS, and obtaining the yam vesicle nanomaterial. In this invention, the yam vesicle nanomaterial uses yam as raw material. The obtained yam vesicle nanomaterial has natural bone marrow targeting properties, requires no additional modification, and can spontaneously accumulate in the bone marrow after intravenous injection, specifically protecting the hematopoietic system. It can also simultaneously prevent the decrease in white blood cells, red blood cells, and platelets caused by radiotherapy, comprehensively alleviating the bone marrow suppression side effects of radiotherapy without affecting the efficacy of tumor radiotherapy.

The invention provides a spleen-tonifying and detoxifying traditional Chinese medicine composition as well as a preparation method and application thereof, and belongs to the technical field of traditional Chinese medicines. The traditional Chinese medicine composition comprises a formula A and a formula B. The traditional Chinese medicine composition has a comprehensive conditioning effect and can relieve chemotherapy side effects, improve intestinal flora distribution, promote intestinal health, enhance the chemotherapy effect and improve the disease control rate. Wherein the formula A focuses on tonifying spleen and regulating qi, and improving nausea, vomiting and other symptoms at the initial stage of chemotherapy, and the formula B is added with medicines for clearing away heat and toxic materials and promoting blood circulation to remove blood stasis on the basis, is suitable for patients with myelosuppression with cancer toxicity residue, and strengthens the effects of clearing away heat and toxic materials and removing stasis; the composition has a multi-target action mechanism, and through the combined action of multiple ways, the treatment effect is enhanced, and the side effect is reduced.

This invention relates to the application of *Bifidobacterium longum* BL21 in the preparation of formulations to alleviate multi-organ damage induced by cisplatin chemotherapy, namely, a novel microbial strategy for preventing or alleviating multi-organ damage induced by cisplatin chemotherapy. This invention creatively discovers that *Bifidobacterium longum* BL21 can alleviate kidney damage, intestinal damage, and bone marrow suppression without interfering with the antitumor activity of cisplatin. Specifically, it can reverse the increase in serum creatinine and blood urea nitrogen levels caused by cisplatin chemotherapy, reverse the increase in inflammatory factor levels in kidney tissue caused by cisplatin chemotherapy, and alleviate oxidative stress damage in kidney tissue caused by cisplatin chemotherapy; it can reverse the increase in intestinal permeability caused by cisplatin chemotherapy, reverse the downregulation of intestinal tight junction protein expression caused by cisplatin chemotherapy, reverse the increase in serum endotoxin levels caused by cisplatin chemotherapy, and reverse the decrease in beneficial intestinal bacteria caused by cisplatin chemotherapy; it can improve hematopoietic dysfunction caused by cisplatin chemotherapy and restore white blood cell count.

This invention discloses a tumor adjuvant nutritional preparation based on *Pterocarya stenoptera* oil, its preparation method, and its application. The active ingredients of this preparation are composed of *Pterocarya stenoptera* oil, ω-3 fatty acids, and arginine in a mass ratio of (1-3):(1-2):(1-2), preferably 2:1:1. The preparation method includes mixing the above components evenly, followed by high-pressure homogenization and aseptic emulsification to produce an oral liquid, enteral nutrition emulsion, or powder. This preparation can effectively improve chemotherapy-induced bone marrow suppression, significantly increase white blood cell, red blood cell, and hemoglobin levels, enhance serum superoxide dismutase activity, reduce oxidative stress damage, and significantly alleviate gastrointestinal adverse reactions such as nausea, vomiting, and loss of appetite in cancer patients undergoing radiotherapy and chemotherapy, improving patients' nutritional status and quality of life, and exhibiting good safety.